The tyrosine kinase Src and its close homolog Abl, both play important roles in chronic myelogenous leukemia (CML) progression and Imatinib resistance. No clin. approved inhibitors of the drug-resistant AblT315I exist to date. Here, we present a thorough kinetic anal. of two potent dual Src-Abl inhibitors towards wild type Src and Abl, and the AblT315I mutant. Our results show that the most potent compd. BO1 (I) shows only a modest loss of potency (fourfold) towards the AblT315I mutant in vitro and was an ATP-competitive inhibitor of wild type Abl but it acted as a non-competitive inhibitor in the case of AblT315I.
Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms
SCHENONE, SILVIA;
2010-01-01
Abstract
The tyrosine kinase Src and its close homolog Abl, both play important roles in chronic myelogenous leukemia (CML) progression and Imatinib resistance. No clin. approved inhibitors of the drug-resistant AblT315I exist to date. Here, we present a thorough kinetic anal. of two potent dual Src-Abl inhibitors towards wild type Src and Abl, and the AblT315I mutant. Our results show that the most potent compd. BO1 (I) shows only a modest loss of potency (fourfold) towards the AblT315I mutant in vitro and was an ATP-competitive inhibitor of wild type Abl but it acted as a non-competitive inhibitor in the case of AblT315I.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
bmc 2010, 18, 3999.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
950.13 kB
Formato
Adobe PDF
|
950.13 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.